Literature DB >> 3592367

Clinical observations in collies given ivermectin orally.

A J Paul, W J Tranquilli, R L Seward, K S Todd, J A DiPietro.   

Abstract

An oral liquid form of ivermectin was administered to 14 purebred Collies (12 rough coated, 2 smooth coated). All Collies were given ivermectin at dosages of 100 and then 200 micrograms/kg of body weight. Three of the dogs developed mild clinical signs of toxicosis (salivation, vomiting, confusion, ataxia, and tremors) with the 100 micrograms/kg dosage. After the 200 micrograms/kg dosage, 7 dogs (including 1 smooth-coated Collie) developed severe toxicosis (seizure-like activity, recumbency, nonresponsiveness, and coma). Because dogs that developed severe toxicosis were not retreated, only the 7 remaining dogs were given ivermectin at 600 micrograms/kg. Severe toxic signs were not observed in the dogs given the 600 micrograms/kg dosage, and only 1 of these 7 dogs developed severe toxicosis when given ivermectin at 2,500 micrograms/kg. Dogs that developed severe toxicosis were given supportive care while in the comatose state. All dogs recovered completely. The results indicated that Collies (including the smooth-coated Collies) have a wide range of sensitivity to ivermectin-induced toxicosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3592367

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  24 in total

1.  Drug-resistant Drosophila indicate glutamate-gated chloride channels are targets for the antiparasitics nodulisporic acid and ivermectin.

Authors:  N S Kane; B Hirschberg; S Qian; D Hunt; B Thomas; R Brochu; S W Ludmerer; Y Zheng; M Smith; J P Arena; C J Cohen; D Schmatz; J Warmke; D F Cully
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

3.  Ivermectin overdose and toxicosis in neonatal pigs.

Authors:  S E Sanford; A J Rehmtulla; G K Josephson
Journal:  Can Vet J       Date:  1988-09       Impact factor: 1.008

4.  Ivermectin toxicity in small animals.

Authors:  S Bauck
Journal:  Can Vet J       Date:  1987-09       Impact factor: 1.008

5.  Binding characteristics of ivermectin in plasma from collie dogs.

Authors:  S P Rohrer; D V Evans
Journal:  Vet Res Commun       Date:  1990       Impact factor: 2.459

Review 6.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Ivermectin excretion by isolated functionally intact brain endothelial capillaries.

Authors:  S Nobmann; B Bauer; G Fricker
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

8.  Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.

Authors:  Catherine Bourguinat; Joseph Kamgno; Michel Boussinesq; Charles D Mackenzie; Roger K Prichard; Timothy G Geary
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

9.  Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs.

Authors:  Feli M Walther; Mark J Allan; Rainer K A Roepke
Journal:  Parasit Vectors       Date:  2015-10-06       Impact factor: 3.876

10.  Moxidectin toxicity in senescence-accelerated prone and resistant mice.

Authors:  Vanessa K Lee; Asheesh K Tiwary; Prachi Sharma-Reddy; Karen A Lieber; Douglas K Taylor; Deborah M Mook
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.